A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an incomplete response to monoaminergic antidepressant drugs, and a biomarker profile predictive of active P2X7 signalling
Latest Information Update: 23 Feb 2024
At a glance
- Drugs JNJ 54175446 (Primary)
- Indications Major depressive disorder
- Focus Biomarker; Therapeutic Use
- Acronyms ATP
Most Recent Events
- 20 Jun 2022 Recruitment completion is expected on 10 Jun 2022, according to ISRCTN: Current Controlled Trials.
- 20 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 10 May 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2024.